<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839461</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0973</org_study_id>
    <nct_id>NCT01839461</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Morphine Spine Study</brief_title>
  <official_title>Personalizing Perioperative Morphine Analgesia for Adolescents Undergoing Major Spine Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to identify factors and genes (the DNA material that
      determines the makeup of the human body) that may be associated with how children respond to
      pain medication. Morphine is a pain medication commonly prescribed after this surgery during
      the hospital stay. The investigators want to study factors that may be associated with pain
      sensitivity, morphine requirement after surgery and side-effects from morphine. The
      investigators expect that the information obtained in this research study will help to
      develop effective, safer, and tailored treatment options in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safe and effective analgesia is an important unmet medical need in children. Despite efforts
      to promote non-pharmacologic interventions, drug treatment remains the standard of care for
      children experiencing severe pain following surgery. Inadequate pain relief after invasive
      surgery, and side effects from analgesics such as morphine occur frequently in up to 50% of
      children. A study of patient-controlled analgesia morphine use after spine surgery in
      adolescents observed a 45% incidence of postoperative nausea and vomiting 15% incidence of
      pruritis and 7% incidence of respiratory depression. Among the drugs available, the opioids,
      specifically morphine is the most commonly employed. Morphine has a narrow therapeutic index,
      with the most fatal toxicity being respiratory depression. For morphine, like most opioids,
      there is a fine balance in dosing regimen between optimal pain control and safety in terms of
      decreasing morphine's respiratory depressant/ sedative side effects. Inadequate pain relief
      and analgesic side effects have major clinical, behavioral and economic consequences. Neither
      evidence-based dosing guidelines nor rigorous documentation of therapeutic benefit for
      morphine has been ascertained in the pediatric patient population. Despite aggressive pain
      management after spine surgery, findings showed that neither children's pain nor their
      analgesic use diminished significantly over time. As such, there is a critical knowledge gap
      in the medical literature that significantly impacts the pediatric pain management. In
      recognition of this therapeutic challenge the investigators plan to evaluate the determinants
      of inter-individual differences in opioid analgesic responsiveness and adverse effects in
      children. Adolescents following spine surgery have a great variability in morphine
      requirements with greater use as they became older. Analgesic dosing is dependent on
      appreciation of the interplay between pharmacokinetics, pharmacodynamics and therapeutics.
      These factors are often poorly understood, where the effective control of procedural pain for
      example, remains problematic. Suitable pharmacological alternatives to opioid treatment for
      moderate to severe pain in children after surgery are limited and consequently there is a
      need for a critical evaluation of the existing opioids and research reports.

      Recently a number of small studies have shown the association of single nucleotide
      polymorphism in genes in the pain pathway, with altered pain response to a stimulus or
      altered response to opioids following a painful procedure. Age, gender, cultural influences,
      anxiety, type of surgical procedure and genetic factors can all influence the response.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immediate postoperative pain scores in the recovery room</measure>
    <time_frame>1 day ( Recovery room)</time_frame>
    <description>Pain score will be measured using standard and validated scales, Numeric rating scale (NRS 0 - 10). This scale has been widely validated and discriminates mild, moderate and severe pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative intravenous morphine requirement</measure>
    <time_frame>First 48 hours after surgery</time_frame>
    <description>Pain score will be measured using standard and validated scales, Numeric rating scale (NRS 0 - 10). This scale has been widely validated and discriminates mild, moderate and severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic pain pre-operatively</measure>
    <time_frame>Pre-operative</time_frame>
    <description>Participants will complete questionnaires regarding pain since surgery was completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic pain post-operatively</measure>
    <time_frame>2 - 6 months post-operative</time_frame>
    <description>Participants will complete questionnaires regarding pain since surgery was completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic pain post-operatively</measure>
    <time_frame>10 - 12 months post-operative</time_frame>
    <description>Participants will complete questionnaires regarding pain since surgery was completed</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Side-effect measures</measure>
    <time_frame>First 48 hours post surgery</time_frame>
    <description>Incidences of respiratory depression, sedation, postoperative nausea and vomiting (PONV) in the recovery phase will be collected.</description>
  </other_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pain</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      De-identified study subjects' genetic information and their responses to pain and pain
      medications, side-effects will be included in a study database. No patient identifiers will
      be included in the database and there will be a confidential (access limited to investigators
      only) code or link between the database and other information about the participant
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children ages 10 to 18, inclusive, years scheduled for spinal surgical procedures.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged 10 to 18, inclusive, years of age

          -  Diagnosis of Idiopathic scoliosis, kyphosis and/or kyphoscoliosis

          -  Scheduled for spine fusion

        Exclusion Criteria:

          -  Known hypersensitivity to morphine

          -  Patients on chronic pain medication.

          -  Pregnant or breastfeeding females.

          -  Children with a history of or active renal or liver disease.

          -  Concomitant use of medication known to induce or inhibit CYP2D6 activity including
             paroxetine, fluoxetine, cimetidine, duloxetine or methadone.

          -  Non-English speaking patients.

          -  Developmental delay.

          -  Children who have problems with pupil or pupillary reaction due to disease (such as
             amyloidosis, bilateral Horner's syndrome, familial dysautonomia, other major
             neurological disorders) or preoperative medications influencing pupillary size
             (anti-cholinergic, narcotic medications such as codeine in cough syrup) will be
             recruited but pupillometry will be deferred.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vidya Chidambaran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Childrens Hospital Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Beaulieu P, Cyrenne L, Mathews S, Villeneuve E, Vischoff D. Patient-controlled analgesia after spinal fusion for idiopathic scoliosis. Int Orthop. 1996;20(5):295-9.</citation>
    <PMID>8930721</PMID>
  </reference>
  <reference>
    <citation>Rahim-Williams FB, Riley JL 3rd, Herrera D, Campbell CM, Hastie BA, Fillingim RB. Ethnic identity predicts experimental pain sensitivity in African Americans and Hispanics. Pain. 2007 May;129(1-2):177-84. Epub 2007 Feb 12.</citation>
    <PMID>17296267</PMID>
  </reference>
  <reference>
    <citation>Rakvåg TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE, Skorpen F. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005 Jul;116(1-2):73-8.</citation>
    <PMID>15927391</PMID>
  </reference>
  <reference>
    <citation>Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain. 2007 Apr;128(3):199-208. Epub 2006 Nov 7.</citation>
    <PMID>17084978</PMID>
  </reference>
  <reference>
    <citation>Diatchenko L, Nackley AG, Slade GD, Bhalang K, Belfer I, Max MB, Goldman D, Maixner W. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain. 2006 Dec 5;125(3):216-24. Epub 2006 Jul 11.</citation>
    <PMID>16837133</PMID>
  </reference>
  <reference>
    <citation>Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005 Jan 1;14(1):135-43. Epub 2004 Nov 10.</citation>
    <PMID>15537663</PMID>
  </reference>
  <reference>
    <citation>Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003 Feb 21;299(5610):1240-3.</citation>
    <PMID>12595695</PMID>
  </reference>
  <reference>
    <citation>Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lötsch J. The mu-opioid receptor gene polymorphism 118A&gt;G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics. 2006 Sep;16(9):625-36.</citation>
    <PMID>16906017</PMID>
  </reference>
  <reference>
    <citation>Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology. 2006 Aug;105(2):334-7.</citation>
    <PMID>16871067</PMID>
  </reference>
  <reference>
    <citation>Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, Lee TH, Concejero A, Hsu CJ. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand. 2006 Aug;50(7):787-92.</citation>
    <PMID>16879459</PMID>
  </reference>
  <reference>
    <citation>Klepstad P, Rakvåg TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F. The 118 A &gt; G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004 Nov;48(10):1232-9.</citation>
    <PMID>15504181</PMID>
  </reference>
  <reference>
    <citation>Reyes-Gibby CC, Shete S, Rakvåg T, Bhat SV, Skorpen F, Bruera E, Kaasa S, Klepstad P. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007 Jul;130(1-2):25-30. Epub 2006 Dec 6.</citation>
    <PMID>17156920</PMID>
  </reference>
  <reference>
    <citation>Pasternak GW. The pharmacology of mu analgesics: from patients to genes. Neuroscientist. 2001 Jun;7(3):220-31. Review.</citation>
    <PMID>11499401</PMID>
  </reference>
  <reference>
    <citation>Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Trégouet D, Descot C, Parc Y, Lienhart A, Jaillon P, Becquemont L. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther. 2006 Apr;79(4):316-24.</citation>
    <PMID>16580900</PMID>
  </reference>
  <reference>
    <citation>Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther. 2006 Dec;80(6):682-90.</citation>
    <PMID>17178268</PMID>
  </reference>
  <reference>
    <citation>Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain. 2008 Dec 18;4:64. doi: 10.1186/1744-8069-4-64.</citation>
    <PMID>19094200</PMID>
  </reference>
  <reference>
    <citation>Gramke HF, de Rijke JM, van Kleef M, Raps F, Kessels AG, Peters ML, Sommer M, Marcus MA. The prevalence of postoperative pain in a cross-sectional group of patients after day-case surgery in a university hospital. Clin J Pain. 2007 Jul-Aug;23(6):543-8.</citation>
    <PMID>17575496</PMID>
  </reference>
  <reference>
    <citation>Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci. 2005 Jun;26(6):311-7. Review.</citation>
    <PMID>15925706</PMID>
  </reference>
  <reference>
    <citation>Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001 Apr;11(3):217-21.</citation>
    <PMID>11337937</PMID>
  </reference>
  <reference>
    <citation>Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001 Aug;70(2):189-99.</citation>
    <PMID>11503014</PMID>
  </reference>
  <reference>
    <citation>Kim H, Neubert JK, San Miguel A, Xu K, Krishnaraju RK, Iadarola MJ, Goldman D, Dionne RA. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain. 2004 Jun;109(3):488-96.</citation>
    <PMID>15157710</PMID>
  </reference>
  <reference>
    <citation>Khasar SG, McCarter G, Levine JD. Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J Neurophysiol. 1999 Mar;81(3):1104-12.</citation>
    <PMID>10085337</PMID>
  </reference>
  <reference>
    <citation>Diatchenko L, Anderson AD, Slade GD, Fillingim RB, Shabalina SA, Higgins TJ, Sama S, Belfer I, Goldman D, Max MB, Weir BS, Maixner W. Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder. Am J Med Genet B Neuropsychiatr Genet. 2006 Jul 5;141B(5):449-62.</citation>
    <PMID>16741943</PMID>
  </reference>
  <reference>
    <citation>Liang DY, Liao G, Wang J, Usuka J, Guo Y, Peltz G, Clark JD. A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology. 2006 May;104(5):1054-62.</citation>
    <PMID>16645459</PMID>
  </reference>
  <reference>
    <citation>Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4.</citation>
    <PMID>9010622</PMID>
  </reference>
  <reference>
    <citation>Hirota T, Ieiri I, Takane H, Sano H, Kawamoto K, Aono H, Yamasaki A, Takeuchi H, Masada M, Shimizu E, Higuchi S, Otsubo K. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos. 2003 May;31(5):677-80.</citation>
    <PMID>12695358</PMID>
  </reference>
  <reference>
    <citation>Duguay Y, Báár C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther. 2004 Mar;75(3):223-33.</citation>
    <PMID>15001974</PMID>
  </reference>
  <reference>
    <citation>Takeda S, Ishii Y, Iwanaga M, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, Yamada H. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol Pharmacol. 2005 Mar;67(3):665-72. Epub 2004 Dec 20.</citation>
    <PMID>15611481</PMID>
  </reference>
  <reference>
    <citation>Smith HS. Opioid metabolism. Mayo Clin Proc. 2009 Jul;84(7):613-24. doi: 10.1016/S0025-6196(11)60750-7. Review.</citation>
    <PMID>19567715</PMID>
  </reference>
  <reference>
    <citation>Schaffer JV, Bolognia JL. The melanocortin-1 receptor: red hair and beyond. Arch Dermatol. 2001 Nov;137(11):1477-85. Review.</citation>
    <PMID>11708951</PMID>
  </reference>
  <reference>
    <citation>Mogil JS, Wilson SG, Chesler EJ, Rankin AL, Nemmani KV, Lariviere WR, Groce MK, Wallace MR, Kaplan L, Staud R, Ness TJ, Glover TL, Stankova M, Mayorov A, Hruby VJ, Grisel JE, Fillingim RB. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4867-72. Epub 2003 Mar 27.</citation>
    <PMID>12663858</PMID>
  </reference>
  <reference>
    <citation>Mogil JS, Ritchie J, Smith SB, Strasburg K, Kaplan L, Wallace MR, Romberg RR, Bijl H, Sarton EY, Fillingim RB, Dahan A. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet. 2005 Jul;42(7):583-7.</citation>
    <PMID>15994880</PMID>
  </reference>
  <reference>
    <citation>Beaumont KA, Newton RA, Smit DJ, Leonard JH, Stow JL, Sturm RA. Altered cell surface expression of human MC1R variant receptor alleles associated with red hair and skin cancer risk. Hum Mol Genet. 2005 Aug 1;14(15):2145-54. Epub 2005 Jun 22.</citation>
    <PMID>15972726</PMID>
  </reference>
  <reference>
    <citation>Crawford MW, Hickey C, Zaarour C, Howard A, Naser B. Development of acute opioid tolerance during infusion of remifentanil for pediatric scoliosis surgery. Anesth Analg. 2006 Jun;102(6):1662-7.</citation>
    <PMID>16717305</PMID>
  </reference>
  <reference>
    <citation>Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003 Nov;106(1-2):49-57.</citation>
    <PMID>14581110</PMID>
  </reference>
  <reference>
    <citation>Vinik HR, Kissin I. Rapid development of tolerance to analgesia during remifentanil infusion in humans. Anesth Analg. 1998 Jun;86(6):1307-11.</citation>
    <PMID>9620525</PMID>
  </reference>
  <reference>
    <citation>Li X, Angst MS, Clark JD. A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res. 2001 Jan 31;86(1-2):56-62.</citation>
    <PMID>11165371</PMID>
  </reference>
  <reference>
    <citation>Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 2002 Sep 15;22(18):8312-23.</citation>
    <PMID>12223586</PMID>
  </reference>
  <reference>
    <citation>King T, Gardell LR, Wang R, Vardanyan A, Ossipov MH, Malan TP Jr, Vanderah TW, Hunt SP, Hruby VJ, Lai J, Porreca F. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain. 2005 Aug;116(3):276-88.</citation>
    <PMID>15964684</PMID>
  </reference>
  <reference>
    <citation>Moises HC, Smith CB. Changes occur in central adrenoreceptor function following long-term morphine treatment and during morphine withdrawal. Neuropeptides. 1984 Dec;5(1-3):29-32.</citation>
    <PMID>6152326</PMID>
  </reference>
  <reference>
    <citation>Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. Anesth Analg. 2003 Sep;97(3):810-5.</citation>
    <PMID>12933407</PMID>
  </reference>
  <reference>
    <citation>Nackley A, Diatchenko L, Maixner W. Perspectives on the genetic basis of opioid-induced hyperalgesia. Anesthesiology. 2006 May;104(5):909-10.</citation>
    <PMID>16645440</PMID>
  </reference>
  <reference>
    <citation>Perquin CW, Hazebroek-Kampschreur AA, Hunfeld JA, Bohnen AM, van Suijlekom-Smit LW, Passchier J, van der Wouden JC. Pain in children and adolescents: a common experience. Pain. 2000 Jul;87(1):51-8.</citation>
    <PMID>10863045</PMID>
  </reference>
  <reference>
    <citation>Duedahl TH, Hansen EH. A qualitative systematic review of morphine treatment in children with postoperative pain. Paediatr Anaesth. 2007 Aug;17(8):756-74. Review.</citation>
    <PMID>17596221</PMID>
  </reference>
  <reference>
    <citation>Anderson BJ, Palmer GM. Recent developments in the pharmacological management of pain in children. Curr Opin Anaesthesiol. 2006 Jun;19(3):285-92. Review.</citation>
    <PMID>16735812</PMID>
  </reference>
  <reference>
    <citation>Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005 Aug;49(7):902-8. Review.</citation>
    <PMID>16045647</PMID>
  </reference>
  <reference>
    <citation>Berde CB, Sethna NF. Analgesics for the treatment of pain in children. N Engl J Med. 2002 Oct 3;347(14):1094-103. Review. Erratum in: N Engl J Med. 2011 May 5;364(18):1782. Dosage error in article text.</citation>
    <PMID>12362012</PMID>
  </reference>
  <reference>
    <citation>Kotzer AM, Foster R. Children's use of PCA following spinal fusion. Orthop Nurs. 2000 Sep-Oct;19(5):19-27; quiz 28-30.</citation>
    <PMID>11153382</PMID>
  </reference>
  <reference>
    <citation>Bringuier S, Dadure C, Raux O, Dubois A, Picot MC, Capdevila X. The perioperative validity of the visual analog anxiety scale in children: a discriminant and useful instrument in routine clinical practice to optimize postoperative pain management. Anesth Analg. 2009 Sep;109(3):737-44. doi: 10.1213/ane.0b013e3181af00e4.</citation>
    <PMID>19690240</PMID>
  </reference>
  <reference>
    <citation>Gibson PR. Anaesthesia for correction of scoliosis in children. Anaesth Intensive Care. 2004 Aug;32(4):548-59. Review.</citation>
    <PMID>15675216</PMID>
  </reference>
  <reference>
    <citation>Hong D, Flood P, Diaz G. The side effects of morphine and hydromorphone patient-controlled analgesia. Anesth Analg. 2008 Oct;107(4):1384-9. doi: 10.1213/ane.0b013e3181823efb.</citation>
    <PMID>18806056</PMID>
  </reference>
  <reference>
    <citation>Sadhasivam S, Cohen LL, Szabova A, Varughese A, Kurth CD, Willging P, Wang Y, Nick TG, Gunter J. Real-time assessment of perioperative behaviors and prediction of perioperative outcomes. Anesth Analg. 2009 Mar;108(3):822-6. doi: 10.1213/ane.0b013e318195c115.</citation>
    <PMID>19224789</PMID>
  </reference>
  <reference>
    <citation>Kain ZN, Mayes LC, Caldwell-Andrews AA, Karas DE, McClain BC. Preoperative anxiety, postoperative pain, and behavioral recovery in young children undergoing surgery. Pediatrics. 2006 Aug;118(2):651-8.</citation>
    <PMID>16882820</PMID>
  </reference>
  <reference>
    <citation>Chen E, Zeltzer LK, Craske MG, Katz ER. Alteration of memory in the reduction of children's distress during repeated aversive medical procedures. J Consult Clin Psychol. 1999 Aug;67(4):481-90.</citation>
    <PMID>10450618</PMID>
  </reference>
  <reference>
    <citation>Merkel SI, Voepel-Lewis T, Shayevitz JR, Malviya S. The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr Nurs. 1997 May-Jun;23(3):293-7.</citation>
    <PMID>9220806</PMID>
  </reference>
  <reference>
    <citation>von Baeyer CL. Numerical rating scale for self-report of pain intensity in children and adolescents: recent progress and further questions. Eur J Pain. 2009 Nov;13(10):1005-7. doi: 10.1016/j.ejpain.2009.08.006. Epub 2009 Sep 17.</citation>
    <PMID>19766028</PMID>
  </reference>
  <reference>
    <citation>von Baeyer CL, Spagrud LJ, McCormick JC, Choo E, Neville K, Connelly MA. Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children's self-reports of pain intensity. Pain. 2009 Jun;143(3):223-7. doi: 10.1016/j.pain.2009.03.002. Epub 2009 Apr 8.</citation>
    <PMID>19359097</PMID>
  </reference>
  <reference>
    <citation>Bulloch B, Tenenbein M. Validation of 2 pain scales for use in the pediatric emergency department. Pediatrics. 2002 Sep;110(3):e33.</citation>
    <PMID>12205283</PMID>
  </reference>
  <reference>
    <citation>Voepel-Lewis T, Marinkovic A, Kostrzewa A, Tait AR, Malviya S. The prevalence of and risk factors for adverse events in children receiving patient-controlled analgesia by proxy or patient-controlled analgesia after surgery. Anesth Analg. 2008 Jul;107(1):70-5. doi: 10.1213/ane.0b013e318172fa9e.</citation>
    <PMID>18635469</PMID>
  </reference>
  <reference>
    <citation>Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69.</citation>
    <PMID>15371986</PMID>
  </reference>
  <reference>
    <citation>Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther. 2004 Nov;76(5):452-66.</citation>
    <PMID>15536460</PMID>
  </reference>
  <reference>
    <citation>Constant I, Nghe MC, Boudet L, Berniere J, Schrayer S, Seeman R, Murat I. Reflex pupillary dilatation in response to skin incision and alfentanil in children anaesthetized with sevoflurane: a more sensitive measure of noxious stimulation than the commonly used variables. Br J Anaesth. 2006 May;96(5):614-9. Epub 2006 Mar 24.</citation>
    <PMID>16565227</PMID>
  </reference>
  <reference>
    <citation>Boev AN, Fountas KN, Karampelas I, Boev C, Machinis TG, Feltes C, Okosun I, Dimopoulos V, Troup C. Quantitative pupillometry: normative data in healthy pediatric volunteers. J Neurosurg. 2005 Dec;103(6 Suppl):496-500.</citation>
    <PMID>16383247</PMID>
  </reference>
  <reference>
    <citation>Gozal D, Ben-Ari JH, Harper RM, Keens TG. Ventilatory responses to repeated short hypercapnic challenges. J Appl Physiol (1985). 1995 Apr;78(4):1374-81.</citation>
    <PMID>7615445</PMID>
  </reference>
  <reference>
    <citation>Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, Du Bois R, Riley J. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5(5):324-36.</citation>
    <PMID>16103897</PMID>
  </reference>
  <reference>
    <citation>Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003 Aug;74(2):102-12.</citation>
    <PMID>12891220</PMID>
  </reference>
  <reference>
    <citation>Kelly PJ, Stallard N, Whittaker JC. Statistical design and analysis of pharmacogenetic trials. Stat Med. 2005 May 30;24(10):1495-508.</citation>
    <PMID>15706636</PMID>
  </reference>
  <reference>
    <citation>Musani SK, Shriner D, Liu N, Feng R, Coffey CS, Yi N, Tiwari HK, Allison DB. Detection of gene x gene interactions in genome-wide association studies of human population data. Hum Hered. 2007;63(2):67-84. Epub 2007 Feb 2. Review.</citation>
    <PMID>17283436</PMID>
  </reference>
  <reference>
    <citation>Gardiner JC, Luo Z, Roman LA. Fixed effects, random effects and GEE: what are the differences? Stat Med. 2009 Jan 30;28(2):221-39. doi: 10.1002/sim.3478.</citation>
    <PMID>19012297</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacogenetics</keyword>
  <keyword>postoperative</keyword>
  <keyword>pediatric</keyword>
  <keyword>opioid</keyword>
  <keyword>perioperative</keyword>
  <keyword>respiratory depression</keyword>
  <keyword>chronic pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

